February 28, 2017 9:01 AM ET

Pharmaceuticals

Company Overview of Shilpa Medicare Limited

Company Overview

Shilpa Medicare Limited manufactures and sells bulk drugs and intermediates in India. The company offers active pharmaceutical ingredients and intermediates for oncology, anti-retro virals, and other therapeutic areas; and formulations, new drug delivery systems, peptides/biotech products, specialty chemicals, etc. It is also involved in the generation of wind power. The company also exports its products. Shilpa Medicare Limited was founded in 1987 and is based in Raichur, India.

Shilpa House

#12-6-214/A1

Hyderabad Road

Raichur,  584135

India

Founded in 1987

Phone:

91 85 3223 6494

Fax:

91 85 3223 5876

Key Executives for Shilpa Medicare Limited

Managing Director and Director
Age: 52
Total Annual Compensation: 14.6M
Compensation as of Fiscal Year 2016.

Shilpa Medicare Limited Key Developments

Shilpa Medicare Ltd Announces Resignation of Venugopal Loya as Independent Director

Shilpa Medicare Ltd. announced that the board has approved the resignation of Mr. Venugopal Loya, Independent Director of the company with effect from February 14, 2017.

Shilpa Medicare Limited Announces Unaudited Standalone and Consolidated Earnings Results for Third Quarter and Nine Months Ended December 31, 2016

Shilpa Medicare Limited announced unaudited standalone and consolidated earnings results for third quarter and nine months ended December 31, 2016. For the quarter, the company reported standalone revenues from operations was INR 1,759.464 million against revenues from operations of INR 1,903.447 million a year ago. Profit from operations before other income and finance costs and exceptional items was INR 344.428 million against profit from operations before other income and finance costs and exceptional items of INR 376.719 million a year ago. Profit before tax was INR 370.097 million against profit before tax of INR 389.676 million a year ago. Net profit was INR 273.469 million against net profit of INR 321.323 million a year ago. Basic and diluted per share was INR 3.31 against Basic and diluted per share of INR 4.17 a year ago. For the period, the company reported standalone revenues from operations was INR 5,309.118 million against revenues from operations of INR 5,004.009 million a year ago. Profit from operations before other income and finance costs and exceptional items was INR 1,037.141 million against profit from operations before other income and finance costs and exceptional items of INR 1,004.744 million a year ago. Profit before tax was INR 1,142.877 million against profit before tax of INR 1,034.47 million a year ago. Net profit was INR 846.263 million against net profit of INR 794.112 million a year ago. Basic and diluted per share was INR 10.74 against Basic and diluted per share of INR 10.32 a year ago. For the quarter, the company reported consolidated revenues from operations of INR 1,835.773 million against revenues from operations of INR 2,000.379 million a year ago. Profit from operations before other income and finance costs and exceptional items was INR 270.644 million against profit from operations before other income and finance costs and exceptional items of INR 360.107 million a year ago. Profit before tax was INR 303.676 million against profit before tax of INR 371.587 million a year ago. Net profit was INR 207.178 million against net profit of INR 304.292 million a year ago. Basic and diluted per share was INR 2.03 against Basic and diluted per share of INR 3.6 a year ago. For the period, the company reported consolidated revenues from operations were INR 5,617.385 million against revenues from operations of INR 5,244.353 million a year ago. Profit from operations before other income and finance costs and exceptional items was INR 945.687 million against profit from operations before other income and finance costs and exceptional items of INR 927.24 million a year ago. Profit before tax was INR 1,026.396 million against profit before tax of INR 953.564 million a year ago. Net profit was INR 726.63 million against net profit of INR 717.252 million a year ago. Basic and diluted per share was INR 8.86 against Basic and diluted per share of INR 8.98 a year ago.

Shilpa Medicare Limited to Report Q3, 2017 Results on Feb 14, 2017

Shilpa Medicare Limited announced that they will report Q3, 2017 results on Feb 14, 2017

Recent Private Companies Transactions

Type
Date
Target
Private Placement
December 1, 2016
--
Merger/Acquisition
June 27, 2016
Navya Biologicals Pvt Ltd
Merger/Acquisition
May 30, 2016
NU Therapeutics Pvt. Ltd.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Shilpa Medicare Limited, please visit www.vbshilpa.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.